Immune cell therapy for recurrent oligodendroglioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a personalized immune cell therapy for adults with a specific type of brain tumor (oligodendroglioma) that has come back. The treatment uses your own immune cells to target the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed oligodendroglioma (IDH-mutant, 1p/19q co-deleted) that has returned or worsened after radiation therapy.
- You are well enough to have surgery or a biopsy.
- You are not taking more than 4 mg of dexamethasone (a steroid) per day.
- You do not have active infections or serious health conditions that would interfere with the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new, personalized cell therapy for children with high-risk neuroblastoma or DIPG (a type of brain tumor) that has come back or is hard to treat. It uses the patient's own tumor to create a treatment that might work better for them.
This trial tests a combination of personalized immune cells, vaccines, stem cells, and an immunotherapy drug (pembrolizumab) for children and young adults whose medulloblastoma has come back or grown. The goal is to help the immune system fight the cancer more effectively.
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
This trial tests a new combination therapy (L19TNF plus a chemotherapy drug like temozolomide or lomustine) for people whose IDH-mutant astrocytoma or oligodendroglioma has returned after earlier chemotherapy. The goal is to see if this combination slows tumor growth safely.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
Hear when a new Recurrent Oligodendroglioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.